|
| 女性绝经后骨质疏松症阿仑膦酸钠联合骨化三醇治疗 的疗效 |
| Efficacy of the combination of alendronate sodium and calcitriol in the treatment of postmenopausal osteoporosis |
| |
| DOI： |
| 中文关键词: 绝经 骨质疏松 阿仑膦酸钠 骨化三醇 |
| 英文关键词:Menopause Osteoporosis Alendronate sodium Calcitriol |
| 基金项目: |
|
| 摘要点击次数: 1040 |
| 全文下载次数: 1123 |
| 中文摘要: |
| 目的分析女性绝经后骨质疏松症患者应用阿仑膦酸钠联合骨化三醇治疗的效果。方法资料随机选自2009年9 月一2012年12月在本院诊治的PMO患者72例，按照年龄分组为A组、B组与C组，其中A组年龄50 -59岁20例，B组年龄 60 -69岁30例，C组年龄70 -79岁22例，均予以阿仑磷酸钠联合骨化三醇，比较三组治疗前后VAS评分、TRACP-5b、BLAP 骨代谢生化等指标。结果予以药物前三组VAS评分、TRACP-5b、BLAP骨代谢生化指标，随年龄增长呈正相关性（P < 0.05)，骨密度值BMD随年龄增长呈负相关性（P <0. 05);治疗后三组VAS评分均有下降，A组下降的幅度均比B、C组多，B 组下降的幅度比C组多（P <0.05);三组骨密度值BMD均有提髙，A组上升幅度，均比B、C组多（P <0.05，P <0. 01)，B组上 升幅度比C组多（P <0.05);三组TRACP-5b、BLAP骨代谢生化指标均降低，A组降低幅度，均比B、C组多（P <0.05，P <0..01）, B组降低幅度比C组多（P <0. 05)。结论不同年龄女性绝经后骨质疏松症应用阿仑膦酸钠联合骨化三醇的效果均 较显著，且疗效与年龄增长呈现负相关性。 |
| 英文摘要: |
| Objective To analyze the efficacy of alendronate sodium combined with calcitriol in the treatment of postmenopausal osteoporosis (PMO). Methods The data of 72 patients with PMO were randomly selected in our hospital from September 2009 to December 2012. According to the age of these patients，the patients were divided into group A (50 -59 years old，n =20)，group B (60 -69 years old，n =30)，and group C (70-79 years old，n =22). The combination of alendronate sodium and calcitriol was given to all patients in these 3 groups. VAS score，TRACP - 5b，and BLAP bone metabolic biochemical markers were compared before and after the treatment. Results VAS score，TRACP - 5b，and BLAP bone metabolic biochemical markers in the 3 groups were positively correlated with the increase of age (P < 0. 05) before the treatment. Bone mineral density (BMD) showed a negative correlation with the increase of age (P <0. 05). After the treatment，VAS score in the 3 groups decreased. The decrease in group A was more than in group B and C，and more in group B than in group C (P <0. 05). BMD in the 3 groups increased. The increase in group A was more than in group B and group C (P <0.05，P <0. 01)，and more in group B than in group C (P < 0.05). Both TRACP-5b and BLAP bone metabolic biochemical markers of the patients in the 3 groups decreased. The decrease in group A was more than in group B and C (P <0.05，P <0. 01)，and more in group B than in group C (P <0. 05). Conclusion Alendronate sodium combined with calcitriol is of significant effect in the treatment of postmenopausal osteoporosis in women with different ages， and the effect is of negatively correlated with the increase of age. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |